TY - JOUR

T1 - Early-stage mantle cell lymphoma

T2 - a retrospective analysis from the International Lymphoma Radiation Oncology Group (ILROG)

AU - Dabaja, B S

AU - Zelenetz, A D

AU - Ng, A K

AU - Tsang, R W

AU - Qi, S

AU - Allen, P K

AU - Hodgson, D

AU - Ricardi, U

AU - Hoppe, R T

AU - Advani, R

AU - Mauch, P M

AU - Constine, L S

AU - Specht, L

AU - Li, Y

AU - Terezakis, S A

AU - Wirth, A

AU - Reinartz, G

AU - Eich, H T

AU - Aleman, B M P

AU - Barr, P

AU - Yahalom, J

N1 - © The Author 2017. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

PY - 2017

Y1 - 2017

N2 - Background: Mantle cell lymphoma (MCL) rarely presents as early-stage disease, but clinical observations suggest that patients who present with early-stage disease may have better outcomes than those with advanced-stage disease.Patients and methods: In this 13-institution study, we examined outcomes among 179 patients with early-stage (stage I or II) MCL in an attempt to identify prognostic factors that influence treatment selection and outcome. Variables examined included clinical characteristics, treatment modality, response to therapy, sites of failure, and survival.Results: Patients were predominantly male (78%) with head and neck being the most common presenting sites (75%). Most failures occurred outside the original disease site (79%). Although the administration of radiation therapy, either alone or with chemotherapy, reduced the risk of local failure, it did not translate into an improved freedom from progression or overall survival (OS). The treatment outcomes were independent of treatment modality. The 10-year OS for patients treated with chemotherapy alone, chemo-radiation therapy and radiation therapy alone were 69%, 62%, and 74% (P = 0.79), and the 10-year freedom from progression were 46%, 43%, and 31% (P = 0.64), respectively.Conclusion: Given the excellent OS rates regardless of initial therapy in patients with early-stage MCL, de-intensified therapy to limit treatment-related toxicity is a reasonable approach.

AB - Background: Mantle cell lymphoma (MCL) rarely presents as early-stage disease, but clinical observations suggest that patients who present with early-stage disease may have better outcomes than those with advanced-stage disease.Patients and methods: In this 13-institution study, we examined outcomes among 179 patients with early-stage (stage I or II) MCL in an attempt to identify prognostic factors that influence treatment selection and outcome. Variables examined included clinical characteristics, treatment modality, response to therapy, sites of failure, and survival.Results: Patients were predominantly male (78%) with head and neck being the most common presenting sites (75%). Most failures occurred outside the original disease site (79%). Although the administration of radiation therapy, either alone or with chemotherapy, reduced the risk of local failure, it did not translate into an improved freedom from progression or overall survival (OS). The treatment outcomes were independent of treatment modality. The 10-year OS for patients treated with chemotherapy alone, chemo-radiation therapy and radiation therapy alone were 69%, 62%, and 74% (P = 0.79), and the 10-year freedom from progression were 46%, 43%, and 31% (P = 0.64), respectively.Conclusion: Given the excellent OS rates regardless of initial therapy in patients with early-stage MCL, de-intensified therapy to limit treatment-related toxicity is a reasonable approach.

U2 - 10.1093/annonc/mdx334

DO - 10.1093/annonc/mdx334

M3 - Journal article

C2 - 28911068

VL - 28

SP - 2185

EP - 2190

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 9

ER -